SubHero Banner

Zepbound (tirzepatide) for weight loss – New drug approval

November 8, 2023 - The FDA announced the approval of Eli Lilly’s Zepbound (tirzepatide), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

— 30 kg/m2 or greater (obesity)

— 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea, or cardiovascular disease).

Download PDF